3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
Sorafenib
79
pembrolizumab
37
Bevacizumab
36
Nivolumab
33
lenvatinib
30
atezolizumab
24
durvalumab
17
Oxaliplatin
12
Ipilimumab
12
regorafenib
9
Capecitabine
9
tremelimumab
8
Injections
8
Doxorubicin
8
tislelizumab
7
sintilimab
7
Fluorouracil
7
cabozantinib
6
budigalimab
6
brivanib
6
Ramucirumab
6
toripalimab
5
Gemcitabine
5
Everolimus
5
Cyclophosphamide
5
ADI PEG20
5
fludarabine
4
Sunitinib
4
Leucovorin
4
E-7386
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Hepatocellular
×
Biopsy, Large-Core Needle
×
Clear all
NCT05520099
2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
416 enrolled